Lead Sponsor

Sanofi

Age

All ages

Sex

ALL

Healthy Volunteers

Yes

•Healthcare professionals working only in Saudi Arabia
•For Prescribers: Orthopedics, Internists, Family Physicians, General Practitioners, Dermatologists, Obstetricians/Gynecologists, Immunologists, and Rheumatologists who prescribed leflunomide to women of childbearing potential in the six months preceding the time of the inclusion
•For Prescribers: Physicians or pharmacists who have prescribed or dispensed leflunomide in a pre-specified period of the 6 months leading up to survey completion
•For Pharmacists: Pharmacists (including clinical pharmacists) who have dispensed leflunomide to women of childbearing potential in the six months preceding the time of the inclusion

•Healthcare professionals who may have conflicts of interest with the survey (i.e., employed by regulatory bodies or pharmaceutical companies)
•Healthcare professionals (with a relative) involved in leflunomide -related lawsuits or associations for victims of leflunomide syndrome
•Healthcare professionals who are not prescribing leflunomide
•Healthcare professionals who have prescribed or dispensed leflunomide earlier than 6 months before the survey completion
•The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Related studies

NCT07486960 · Psoriatic Arthritis

NCT07536529 · Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), and more

NCT06329401 · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, and more

NCT07048197 · Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)

NCT07484243 · Rheumatoid Arthritis (RA), Rheumatoid Arthritis-Associated Interstitial Lung Disease, and more

A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia